CureVac’s Independent Journey Concludes Following BioNTech Acquisition

A definitive chapter has closed for investors in CureVac. The German biotech firm’s standalone history as a publicly traded company has reached its conclusion, marking the end of a period characterized by high hopes, subsequent setbacks, and complex patent litigation. The company’s shares have now been permanently removed from listing, with all future operations concerning its mRNA technology and intellectual property to be managed under the umbrella of its industry peer, BioNTech.

Market Listing Formally Withdrawn

The market responded immediately to the finalization of the takeover. Trading in CureVac stock was halted on the Nasdaq Global Market as of today, rendering any further buy or sell orders through the exchange impossible. The ticker symbol is being administratively removed.

The official timeline for the delisting process is as follows:

• January 6, 2026: Merger completion and suspension of Nasdaq trading.
• January 16, 2026: Official delisting from the Nasdaq exchange.
• Approximately 90 days after filing Form 15: The deregistration with the U.S. Securities and Exchange Commission (SEC) becomes effective.

Recent market activity underscored the equity’s final decline. In the week leading up to the halt, the share price fell by more than 13%. Its final closing price of 3.89 euros settled notably below both the 50-day and 200-day moving averages, cementing a clear downward trajectory for its last days of trading, despite remaining above its 52-week low.

Full Integration Under BioNTech

BioNTech officially completed its acquisition of CureVac on January 6, 2026, and now holds 100% of the company’s shares. According to recent SEC filings (Form 6-K), BioNTech is the sole owner of the former CureVac N.V.

Should investors sell immediately? Or is it worth buying CureVac?

As part of the transaction, the corporate structure was revised. The successor entity now operates under the name CureVac Merger B.V. This change has a direct consequence for the market: there is no longer any freely tradable public float, and the former CureVac share has ceased to function as a listed security.

A core objective of the acquisition is the consolidation of expertise and intellectual property rights within the mRNA technology sector. The agreement resolves protracted patent disputes between the two firms while transferring key rights to technology platforms under BioNTech’s control. For the investment community, this signals that the market’s “mRNA narrative,” once closely tied to CureVac, is now entirely centered on BioNTech.

Analyst Coverage Ceases

The delisting not only removes the stock from the market but also ends independent analyst coverage. Research firm AlphaValue announced today that it is discontinuing its coverage of CureVac. Given that CureVac will be fully integrated into BioNTech, maintaining separate research on the entity is no longer practical.

This step finalizes CureVac’s independent equity story. The relevant assets—primarily patents and technology platforms—are already incorporated into BioNTech’s structure. The necessary amendments to BioNTech’s articles of association to facilitate this integration took effect on December 30, 2025. For former CureVac shareholders, BioNTech becomes the primary point of reference for the future development and commercialization of the acquired mRNA technology.